Permira Advisers LLP completed the acquisition of Ergomed plc for £703.1 million. Ergomed is a differentiated Pharmacovigilance (PV) and contract research organization (CRO) platform with a strong track record in the complex oncology and rare diseases spaces and a reputation for high-quality, bespoke, customer centric delivery across its services.

Ergomed operates in growing markets which benefit from increasing complexity, regulatory requirements, and outsourcing rates. Ergomed has strengthened both CRO and PV capabilities organically and through acquisitions.

Permira deploys capital and expertise into growth-orientated businesses and partnering with founders and management teams in achieving their strategic ambitions. Permira’s industry-specific knowledge and strong network in the healthcare space will allow it to support the next phase of growth for Ergomed by investing in the business’ commercial expansion, technology transformation and geographic reach, as well as providing additional capital to undertake strategic acquisitions.

Miroslav Reljanović, executive chairman of Ergomed, said: “With a strong commitment to service quality and customer service, Ergomed has grown significantly to become a global, geographically diversified player in the CRO and PV sectors. Permira is a highly experienced healthcare investor with a track record of building successful global businesses, which will support us to build on the foundations we have created. Permira brings operational expertise, a global network, capital and, equally importantly, a like-minded approach to how to accelerate our growth. We believe the acquisition will significantly increase our ability to invest in our geographical expansion, commercial infrastructure, and technology, and to execute strategic M&A in both the CRO and PV businesses.”

Silvia Oteri, partner, and global head of healthcare at Permira, said: “We are delighted to complete the acquisition of Ergomed, a medic-led, high quality and fast-growing pharma services platform. It is a privilege to be partnering with Miro and his team, who had the vision of creating a leading outsourcing partner in pharmacovigilance and in oncology and rare disease clinical development, helping clients safely develop and commercialize complex and often life-saving therapies for patients. Through this partnership, we will help Miro and the team to further build and accelerate on the very strong foundation they have already laid.”